Live Breaking News & Updates on Neogenomics Company Profile
Stay updated with breaking news from Neogenomics company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Parkman Healthcare Partners LLC lowered its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 3.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 237,762 shares of the medical research company’s stock after selling 8,050 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in NeoGenomics were worth $3,847,000 as […] ....
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report)’s share price rose 8.8% during trading on Wednesday . The company traded as high as $14.37 and last traded at $14.32. Approximately 505,729 shares changed hands during trading, a decline of 41% from the average daily volume of 858,388 shares. The stock had previously closed at $13.16. Analyst […] ....
Mckinley Capital Management LLC increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 32.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 183,610 shares of the medical research company’s stock after acquiring an additional 45,260 shares during the period. Mckinley […] ....
Handelsbanken Fonder AB lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 7.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,900 shares of the medical research company’s stock after acquiring an additional 1,300 shares during the period. Handelsbanken Fonder AB’s holdings in NeoGenomics were worth $322,000 as of […] ....
Benchmark reaffirmed their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $18.00 price objective on the medical research company’s stock. Other research analysts also recently issued reports about the company. William Blair restated an outperform rating […] ....